Navigation Links
Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
Date:3/15/2011

SAN DIEGO, March 15, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent 7,906,489 which covers methods of Clostridium difficile infection (CDI) treatment with fidaxomicin.  The patent, which is eligible for listing in the U.S. Food and Drug Administration's Orange Book, also received a term adjustment of an additional 762 days for the USPTO's delay in the examination process which extends the patent term to March 2027.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

"The issuance of this patent provides strong intellectual property protection for fidaxomicin, enhancing our drug candidate's present value," said Pedro Lichtinger, President and CEO of Optimer.  "Fidaxomicin is now protected by four issued patents and we are continuing our efforts to expand our patent portfolio for this important medical innovation."

Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment CDI. In two Phase 3 trials, fidaxomicin was equally effective in clinical cure when compared to vancomycin, the only FDA approved product for CDI.  Most importantly, fidaxomicin reduced the risk of recurrence by 47% compared to vancomycin.  Optimer has filed marketing applications in the United States and the European Union for fidaxomicin for the treatment of CDI and for reducing the risk of recurrence when used for treatment of initial CDI.

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fid
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 genae, a ... industries, announced today the incorporation of genae UK in ... has one of the largest medical device markets in the ... it is projected to increase by a CAGR of 6.0% until ... equal to 9.5% of GDP. Despite recessionary pressures, market growth rates ...
(Date:7/31/2014)... 31, 2014 Astellas has appointed ... and employee communications in the Americas region. Knight ... senior vice president, chief communications officer. In this ... leading corporate brand initiatives and reputation management to ... South America . She will ...
(Date:7/31/2014)... -- The Galien Foundation today announced the 2014 nominees ... Awards. The Prix Galien Award is considered ... scientific and clinical research skills necessary to develop innovative ... highest number of nominees since the inception of the ... biomedical products across three categories – biotechnology, pharmaceutical, and ...
Breaking Medicine Technology:genae Opens Offices in London 2Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 3The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 4The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 5
... 5, 2011 SyncMedical LLC today announced ... – Brazilian National Health Surveillance Agency) has approved their ... in Brazil. SyncMedical,s Ethos Spine product line was developed ... treatment solutions to surgeons in the ever-growing, ever-changing field ...
... Jan. 5, 2011 Heska Corporation (Nasdaq: HSKA ... Conference hosted by Sidoti & Company, LLC on Monday, January ... 42nd Street (Park Avenue at Grand Central) in New York ... Eastern Time. (Logo:   http://photos.prnewswire.com/prnh/20000622/HESKALOGO ) ...
Cached Medicine Technology:SyncMedical Receives ANVISA Regulatory Approval to Offer Spine and Internal Medicine Products in Brazil 2
(Date:7/31/2014)... 2014 0-6 Pack Abs has finally been ... therapist expert Dr. James Vegher. Together they have launched ... relieve digestive issues, tone core muscles, improve posture, eliminate achy ... core exercises used to re-train the body in order to ... 0-6 Pack Abs review, Shane Michaels, a fitness ...
(Date:7/31/2014)... In today’s world, a good night’s sleep has ... sleep apnea (a medical problem where the airway collapses during ... of the rest they need to face their daily challenges. ... 20 million people in the United States alone have sleep ... and of those treated, many cannot tolerate their prescribed medical ...
(Date:7/31/2014)... Hook Your Ex, a system created by Steve Pratt, ... hungry for their partner, to the point of starvation, that they ... has been taught to hundreds of men and women across the ... Ex review , Shane Michaels agrees this simple trick is genius ... a second chance at getting back together with their ex. ...
(Date:7/31/2014)... 2014 Jeremiah’s Tavern ... wood to create a unique atmosphere and highlight ... features reclaimed barn siding on the ... mixed softwoods flowing throughout the interior as flooring. ... sister company New Energy Works Timberframers ...
(Date:7/31/2014)... US Hair Restoration Founder, Dr. Parsa Mohebi, has recently ... Mohebi Hair Restoration. Since first opening in 2008, US ... and around the world, who traveled to one of its ... patients achieved the full benefits of a variety of hair ... Dr. Mohebi. They have come to understand how his ...
Breaking Medicine News(10 mins):Health News:Zero To Six Pack Abs System Review Exposes Tyler Bramlett And Dr. James Veghers’ New Ab Training Program 2Health News:Zero To Six Pack Abs System Review Exposes Tyler Bramlett And Dr. James Veghers’ New Ab Training Program 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Hook Your Ex Review by Shane Michaels Exposes Steve Pratt And His New Method For Getting Back With The Ex 2Health News:Popular Tavern Restaurant Features Pioneer Millworks’ Reclaimed Wood in New Locations 2Health News:US Hair Restoration Becomes Parsa Mohebi Hair Restoration 2
... GAP, Pa., April 1, 2008 Core People ... Service Corporation,(CCSC) of Wexford, PA. CCSC provides options ... benefits for Pennsylvania chamber members through,its ChamberChoice portfolio., ... to offer a,broader level of employer services, including ...
... Awareness among Hispanic Community as Fewer ... Receiving Diagnosis and Support, CHICAGO, April 1, ... individuals living with autism, among the,vast array of services the national ... the last 20 years, Easter Seals has seen a dramatic increase ...
... rates to that from younger donors , , TUESDAY, April ... 75 should be allowed to donate corneas for transplant, says ... that tissue from donors aged 66 to 75 had the ... aged 12 to 65. , The research, coordinated by the ...
... the pharmaceutical industry currently underway will increase in the ... researcher at the National Institutes of Health (NIH) who ... development. , According to Christopher Austin, M.D., ... industry and academia welcome more cooperation in drug discovery ...
... CHICAGO, Ill. (April 1, 2008) Many patients ... percutaneous coronary intervention (PCI) are already taking 75mg ... Even so, an additional 600-mg reloading dose of ... risk of bleedingbut only in patients with acute ...
... 1, 2008 Senetek PLC (OTC,Bulletin Board: SNKTY), ... technologies that target the science of healthy aging, ... has secured financing in an,amount up to $28 ... of men,s health treatments, including Invicorp(R)., Plethora ...
Cached Medicine News:Health News:Core People Partners to Expand Services 2Health News:Easter Seals Notes April's Autism Awareness Month to Highlight Services Available to Families Living With Autism 2Health News:Easter Seals Notes April's Autism Awareness Month to Highlight Services Available to Families Living With Autism 3Health News:Study Finds Older Corneas Suitable for Transplantation 2Health News:Business of drug development on verge of great change 2Health News:Clopidogrel reloading worthwhile in acute coronary syndromes 2Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 2Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 3Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: